Cerebrospinal fluid C9 in demyelinating disease.

Area of Science:

• Neuroimmunology
• Neurology
• Biochemistry

Background:

• Demyelinating diseases, including multiple sclerosis (MS), involve complex pathological mechanisms.
• The role of the complement system and humoral immunity in demyelination requires further elucidation.

Purpose of the Study:

• To investigate the concentrations of complement component 9 (C9) and immunoglobulin G (IgG) in cerebrospinal fluid (CSF) and plasma of patients with demyelinating diseases.
• To compare these concentrations between patients with MS, isolated demyelinating lesions, and other neurologic diseases.

Main Methods:

• CSF and plasma samples were collected from 91 patients with demyelination and 73 controls.
• Concentrations of C9, IgG, and albumin were measured using established laboratory assays.
• Indices (CSF/plasma ratios) for C9 and IgG were calculated.

Main Results:

• A reduced C9 index and an increased IgG index were observed in patients with MS and isolated demyelinating lesions.
• These abnormalities were present regardless of disease activity.
• The magnitude of these changes was more pronounced in MS patients compared to those with isolated lesions.

Conclusions:

• While humoral mechanisms may not initiate demyelination, complement system activation appears to amplify tissue damage.
• Complement system activation could contribute to symptomatic recovery in demyelinating diseases.
• These findings highlight the potential involvement of the complement cascade in the pathophysiology of MS and related disorders.